AbbVie Inc. (ABBV) Reaches $102.12 High on Jan, 16; Credit Agricole S.A. (CRARY) Had 2 Analysts Last Week

January 16, 2018 - By Marguerite Chambers

The stock of AbbVie Inc. (NYSE:ABBV) reached all time high today, Jan, 16 and still has $105.18 target or 3.00% above today’s $102.12 share price. This indicates more upside for the $163.03B company. This technical setup was reported by Barchart.com. If the $105.18 PT is reached, the company will be worth $4.89B more. The stock increased 1.77% or $1.7795 during the last trading session, reaching $102.1195. About 1.79 million shares traded. AbbVie Inc. (NYSE:ABBV) has risen 10.63% since January 16, 2017 and is uptrending. It has underperformed by 6.07% the S&P500.

Among 3 analysts covering Credit Agricole SA (OTCMKTS:CRARY), 2 have Buy rating, 1 Sell and 0 Hold. Therefore 67% are positive. Credit Agricole SA had 4 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Macquarie Research given on Friday, November 6. Macquarie Research upgraded the shares of CRARY in report on Monday, October 3 to “Outperform” rating. The rating was initiated by Credit Suisse with “Outperform” on Friday, September 16. The stock has “Underweight” rating by JP Morgan on Wednesday, August 5. See Credit Agricole S.A. (OTCMKTS:CRARY) latest ratings:

The stock increased 0.97% or $0.0899 during the last trading session, reaching $9.3199. About 9,573 shares traded. Credit Agricole S.A. (OTCMKTS:CRARY) has 0.00% since January 16, 2017 and is . It has underperformed by 16.70% the S&P500.

Credit Agricole S.A. provides retail, corporate, insurance, and investment banking services and products worldwide. The company has market cap of $51.99 billion. The firm operates through five divisions: Asset gathering; French Retail Banking – LCL; International Retail Banking; Specialised Financial Services; and Large customers. It has a 14.04 P/E ratio. It offers payment instruments, loans, saving products, and payment management services and products; and savings/retirement, death and disability/creditor/group, and property and casualty insurance products.

Analysts await AbbVie Inc. (NYSE:ABBV) to report earnings on January, 26. They expect $1.43 earnings per share, up 19.17% or $0.23 from last year’s $1.2 per share. ABBV’s profit will be $2.28 billion for 17.85 P/E if the $1.43 EPS becomes a reality. After $1.41 actual earnings per share reported by AbbVie Inc. for the previous quarter, Wall Street now forecasts 1.42% EPS growth.

Among 21 analysts covering Abbvie Inc (NYSE:ABBV), 11 have Buy rating, 1 Sell and 9 Hold. Therefore 52% are positive. Abbvie Inc had 70 analyst reports since July 21, 2015 according to SRatingsIntel. UBS maintained AbbVie Inc. (NYSE:ABBV) rating on Friday, October 23. UBS has “Buy” rating and $78 target. The company was maintained on Friday, April 28 by BMO Capital Markets. The stock of AbbVie Inc. (NYSE:ABBV) has “Market Perform” rating given on Monday, June 6 by Cowen & Co. Jefferies maintained AbbVie Inc. (NYSE:ABBV) on Monday, May 29 with “Buy” rating. Leerink Swann maintained the shares of ABBV in report on Monday, October 30 with “Outperform” rating. The stock of AbbVie Inc. (NYSE:ABBV) has “Buy” rating given on Tuesday, February 23 by Citigroup. The rating was upgraded by Leerink Swann on Monday, October 2 to “Outperform”. Jefferies maintained AbbVie Inc. (NYSE:ABBV) rating on Monday, June 26. Jefferies has “Buy” rating and $9000 target. The firm earned “Buy” rating on Friday, August 18 by Jefferies. The rating was upgraded by Morgan Stanley to “Overweight” on Monday, November 2.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company has market cap of $163.03 billion. The firm offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It has a 24.8 P/E ratio. It also provides Kaletra, an anti- human immunodeficiency virus-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants.

Investors sentiment decreased to 0.85 in Q3 2017. Its down 0.15, from 1 in 2017Q2. It dropped, as 55 investors sold AbbVie Inc. shares while 640 reduced holdings. 132 funds opened positions while 462 raised stakes. 1.06 billion shares or 1.89% more from 1.04 billion shares in 2017Q2 were reported. Auxier Asset Mngmt holds 0.41% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 22,775 shares. Tdam Usa Incorporated invested in 2.2% or 420,723 shares. Invsts Asset Management Of Georgia Incorporated Ga Adv reported 11,420 shares stake. Utd Savings Bank stated it has 9,670 shares or 0.34% of all its holdings. Blair William Il, a Illinois-based fund reported 814,452 shares. 244,984 are owned by Cibc World Markets. Moreover, Amg Trust State Bank has 0.48% invested in AbbVie Inc. (NYSE:ABBV). Aviance Cap Llc stated it has 166,607 shares. Kayne Anderson Rudnick Inv Llc has invested 0% in AbbVie Inc. (NYSE:ABBV). Oak Associates Oh invested in 0.03% or 4,940 shares. Perella Weinberg Partners Capital Mngmt L P has invested 0.17% in AbbVie Inc. (NYSE:ABBV). Ims Management has 0.83% invested in AbbVie Inc. (NYSE:ABBV). Ray Gerald L & Assocs Ltd owns 29,427 shares or 0.33% of their US portfolio. Kistler holds 0.27% of its portfolio in AbbVie Inc. (NYSE:ABBV) for 7,321 shares. Milestone Group has 0.06% invested in AbbVie Inc. (NYSE:ABBV).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.



Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: